The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure

被引：34

作者：

Nazha, Aziz ^{[1
,2
]}

Komrokji, Rami S. ^{[3
]}

Garcia-Manero, Guillermo ^{[4
]}

Barnard, John ^{[5
]}

Roboz, Gail J. ^{[6
]}

Steensma, David P. ^{[7
]}

DeZern, Amy E. ^{[8
]}

Zell, Katrina ^{[5
]}

Zimmerman, Cassie ^{[1
,2
]}

Al Ali, Najla ^{[3
]}

Jabbour, Elias ^{[4
]}

Greenberg, Molly D. ^{[6
]}

Kantarjian, Hagop M. ^{[4
]}

Maciejewski, Jaroslaw P. ^{[1
,2
]}

List, Alan F. ^{[3
]}

Sekeres, Mikkael A. ^{[1
,2
]}

机构：

[1] Cleveland Clin, Leukemia Program, Cleveland, OH 44106 USA

[2] Cleveland Clin, Dept Translat Hematol & Oncol Res, Cleveland, OH 44106 USA

[3] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA

[4] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[5] Cleveland Clin, Dept Quantitat Hlth Sci, Cleveland, OH 44106 USA

[6] New York Presbyterian Hosp, Weill Cornell Med Coll, Div Hematol & Oncol, New York, NY USA

[7] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA

[8] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

来源：

HAEMATOLOGICA | 2016年 / 101卷 / 06期

关键词：

MDS; hypomethylating agent; prognostic models; SCORING SYSTEM; CLASSIFICATION; AZACITIDINE; PROPOSAL;

D O I：

10.3324/haematol.2015.140962

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：E224 / E227

页数：4

共 43 条

[31] Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy
Prebet, Thomas
Cluzeau, Thomas
Park, Sophie
Sekeres, Mikkael A.
Germing, Ulrich
Ades, Lionel
Platzbecker, Uwe
Gotze, Katharina
Vey, Norbert
Oliva, Esther
Sugrue, Mary M.
Bally, Cecile
Kelaidi, Charikleia
Al Ali, Najla
Fenaux, Pierre
Gore, Steven D.
Komrokji, Rami
ONCOTARGET, 2017, 8 (47) : 81926 - 81935
[32] Adding molecular data to prognostic models can improve predictive power in treated patients with myelodysplastic syndromes
Nazha, A.
Al-Issa, K.
Hamilton, B. K.
Radivoyevitch, T.
Gerds, A. T.
Mukherjee, S.
Adema, V.
Zarzour, A.
Abuhadra, N.
Patel, B. J.
Hirsch, C. M.
Advani, A.
Przychodzen, B.
Carraway, H. E.
Maciejewski, J. P.
Sekeres, M. A.
LEUKEMIA, 2017, 31 (12) : 2848 - 2850
[33] Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial
Garcia-Manero, Guillermo
Fenaux, Pierre
Al-Kali, Aref
Baer, Maria R.
Sekeres, Mikkael A.
Roboz, Gail J.
Gaidano, Gianluca
Scott, Bart L.
Greenberg, Peter
Platzbecker, Uwe
Steensma, David P.
Kambhampati, Suman
Kreuzer, Karl-Anton
Godley, Lucy A.
Atallah, Ehab
Collins, Robert, Jr.
Kantarjian, Hagop
Jabbour, Elias
Wilhelm, Francois E.
Azarnia, Nozar
Silverman, Lewis R.
LANCET ONCOLOGY, 2016, 17 (04) : 496 - 508
[34] Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents
Montalban-Bravo, Guillermo
Jabbour, Elias
Borthakur, Gautam
Kadia, Tapan
Ravandi, Farhad
Chien, Kelly
Pemmaraju, Naveen
Hammond, Danielle
Dong, Xiao Qin
Huang, Xuelin
Schneider, Heather
John, Rosmy
Kanagal-Shamana, Rashmi
Loghavi, Sanam
Kantarjian, Hagop
Garcia-Manero, Guillermo
BRITISH JOURNAL OF HAEMATOLOGY, 2024, 204 (03) : 898 - 909
[35] In patients with myelodysplastic syndromes with del(5q), factors other than age and sex contribute to the prognostic advantage, which diminishes over time
Lauseker, Michael
Schemenau, Jennifer
Strupp, Corinna
Undgen, Andrea K.
Gattermann, Norbert
Hasford, Joerg
Germing, Ulrich
BRITISH JOURNAL OF HAEMATOLOGY, 2015, 170 (05) : 687 - 693
[36] Bone marrow fibrosis in patients with primary myelodysplastic syndromes has prognostic value using current therapies and new risk stratification systems
Fu, Bin
Jaso, Jesse M.
Sargent, Rachel L.
Goswami, Maitrayee
Verstovsek, Srdan
Medeiros, L. Jeffrey
Wang, Sa A.
MODERN PATHOLOGY, 2014, 27 (05) : 681 - 689
[37] Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: Retrospective analysis of survival after long-term follow-up
Cabrero, Monica
Jabbour, Elias
Ravandi, Farhad
Bohannan, Zach
Pierce, Sherry
Kantarjian, Hagop M.
Garcia-Manero, Guillermo
LEUKEMIA RESEARCH, 2015, 39 (05) : 520 - 524
[38] Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents
Park, Sophie
Hamel, Jean-Francois
Toma, Andrea
Kelaidi, Charikleia
Thepot, Sylvain
Campelo, Maria Diez
Santini, Valeria
Sekeres, Mikkael A.
Balleari, Enrico
Kaivers, Jennifer
Sapena, Rosa
Goetze, Katharina
Mueller-Thomas, Catharina
Beyne-Rauzy, Odile
Stamatoullas, Aspasia
Kotsianidis, Ioannis
Komrokji, Rami
Steensma, David P.
Fensterl, Jaime
Roboz, Gail J.
Bernal, Teresa
Ramos, Fernando
Calabuig, Marisa
Guerci-Bresler, Agnes
Bordessoule, Dominique
Cony-Makhoul, Pascale
Cheze, Stephane
Wattel, Eric
Rose, Christian
Vey, Norbert
Gioia, Daniela
Ferrero, Dario
Gaidano, Gianluca
Cametti, Giovanni
Pane, Fabrizio
Sanna, Alessandro
Germing, Ulrich
Sanz, Guillermo F.
Dreyfus, Francois
Fenaux, Pierre
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (14) : 1591 - +
[39] Improving accuracy of prognosis in patients with myelodysplastic syndromes using self-reported quality of life data. Opportunities for a new research agenda in developing prognostic models
Niscola, Pasquale
Mandelli, Franco
Efficace, Fabio
EXPERT REVIEW OF HEMATOLOGY, 2016, 9 (05) : 415 - 417
[40] The Sequential Organ Failure Assessment score for predicting outcome in patients with severe sepsis and evidence of hypoperfusion at the time of emergency department presentation
Jones, Alan E.
Trzeciak, Stephen
Kline, Jeffrey A.
CRITICAL CARE MEDICINE, 2009, 37 (05) : 1649 - 1654

← 1 2 3 4 5 →